Bluebird, Celgene myeloma therapy improves with time, study finds
CAR-T treatment removes patient's own immune system cells and tweaking them to attack the cancer
Minneapolis
A novel therapy from Bluebird Bio Inc and Celgene Corp for patients nearing death from an aggressive form of blood cancer appears to get more effective over time, wiping out signs of disease in more than half of those treated in a small trial.
A single infusion of the personalised therapy known as bb2121 generated a response in all but one of the 18 multiple myeloma patients treated at the highest dose, according to the study presented at the American Society of Haematology meeting in Atlanta. After nine months, 56 per cent were in remission. That is an improvement since May, when an earlier look at the data found that 27 per cent of the patients experienced a complete response.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years